Royalty Pharma PLC (RPRX)
| Market Cap | 29.86B |
| Revenue (ttm) | 2.26B |
| Net Income (ttm) | 466.10M |
| Shares Out | 675.95M |
| EPS (ttm) | 1.03 |
| PE Ratio | 42.88 |
| Forward PE | 14.81 |
| Dividend | $0.74 (1.68%) |
| Ex-Dividend Date | Aug 18, 2022 |
| Volume | 1,024,921 |
| Open | 44.00 |
| Previous Close | 44.46 |
| Day's Range | 43.90 - 44.26 |
| 52-Week Range | 34.86 - 44.75 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 55.43 (+25.5%) |
| Earnings Date | Aug 4, 2022 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies an... [Read more...]
Financial Performance
In 2021, Royalty Pharma's revenue was $2.29 billion, an increase of 7.87% compared to the previous year's $2.12 billion. Earnings were $619.73 million, a decrease of -36.44%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for RPRX stock is "Buy." The 12-month stock price forecast is 55.43, which is an increase of 25.49% from the latest price.
News
Three Stock Lunch: Ally Financial, Amazon and Royalty Pharma
Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss her take on three stocks: Ally Financial, Amazon and Royalty Pharma.
Warren Buffett Ramps Up Occidental and Apple Stakes, Dumps Verizon
Warren Buffett (Trades, Portfolio)'s multibillion-dollar conglomerate, Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial), disclosed its equity portfolio for the second quarter of 2022 on ...
Buffett's Berkshire more than triples Ally stake, sheds Verizon
Warren Buffett's Berkshire Hathaway Inc on Monday said it more than tripled its stake in the online banking company Ally Financial Inc, while shedding its stakes in Verizon Communications Inc and Royalt...
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA fil...
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.28% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma Reports Second Quarter 2022 Results
NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipt...
Blueprint Medicines Reports Second Quarter 2022 Results
-- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- Plan to report topli...
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Declares Third Quarter 2022 Dividend
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary...
Theravance sets up deal to sell rights to asthma drug to Royalty Pharma
Shares of Theravance Biopharma Inc. TBPH, -0.80% were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's GSK, -1.25% Tre...
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, toda...
Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion a...
NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc...
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Up...
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of ...
Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion
Shares of Blueprint Medicines Corp. BPMC, -2.34% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma RPRX, -1.10% , which...
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: ...
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and R...
Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic busine...
Royalty Pharma (RPRX) Surges 5.2%: Is This an Indication of Further Gains?
Royalty Pharma (RPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas...
5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began
One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 20...
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET.
Royalty Pharma (RPRX) Lags Q1 Earnings Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of -15.28% and 3.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma Reports First Quarter 2022 Results
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Recei...
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Declares Second Quarter 2022 Dividend
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordin...